Precision coordination of therapeutic and prophylactic antibiotics to reduce infection, toxicity, and emergence of resistance following acute abdominal surgery

精确协调治疗性和预防性抗生素,以减少急腹手术后的感染、毒性和耐药性的出现

基本信息

  • 批准号:
    10458602
  • 负责人:
  • 金额:
    $ 46.62万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-08-01 至 2026-07-31
  • 项目状态:
    未结题

项目摘要

Acute appendicitis is the most common abdominal surgical emergency in the world, with a lifetime risk of 8.6% in males and 6.9% in females. In the U.S., acute appendicitis affects > 280,000 individuals and contributes to 1 million patient days of admission each year. Surgical site infection (SSI) rates following appendectomy for uncomplicated, non-perforated appendicitis remain unacceptably high. A recent review reported pelvic abscess rates of 9.4% following appendectomy. The highest risks for microbial contamination of the peritoneum occur when the appendix is transected. Regardless of surgical technique, the retained appendiceal stump ALWAYS exposes appendiceal mucosa and luminal bacteria to the normally sterile peritoneal cavity. It is thus critical that optimal antibiotic tissue exposure occurs during this operative risk window. Antibiotic intervention for acute appendicitis is complex. Therapeutic antibiotics are initiated empirically in the emergency department, often hours before the appendectomy (usually a 4-18 hour wait). Thus, at the time of surgery, there are already therapeutic antibiotics on board, and the role of prophylactic antibiotics is unclear. To date, there has been no consensus on the blended use of therapeutic and prophylactic antibiotics for acute surgeries, and in many cases, prophylaxis is not administered because therapeutic antibiotics have already been administered. Unfortunately, in these instances antibiotic tissue levels are likely below the minimum inhibitory concentration at the time of appendiceal transection due to the short half-life and lack of protocoled dose timing relative to surgical incision. Consequently, the appendix, a known microbiome reservoir for the colon, has its lumen open to the peritoneum during appendectomy, guaranteeing some level of tissue and peritoneal microbial contamination during the surgery, increasing risk for SSI and abscess formation. A more personalized method of dosing antibiotics in patients with acute appendicitis could reduce SSI risk, limit unnecessary antibiotic use, reduce overdosing risks, and curb the development of antibiotic resistance. We hypothesize that personalized antibiotic dosing based on time to surgical appendectomy can optimize tissue antibiotic exposure at the surgical site, avoid use of unnecessary antibiotics (selective antibiotic resistance pressure), and reduce toxicity. Our Specific Aims are therefore to 1) characterize the plasma, tissue and surgical site tissue concentration of therapeutic antibiotics in patients undergoing appendectomy; 2) design a precision dosing nomogram for therapeutic beta-lactam antibiotics using quantitative tissue PK-PD modeling and simulation that factors antimicrobial susceptibility distributions, patient demographics and morphotypes as well as timing to achieve optimal tissue exposure at appendectomy; and 3) pilot and evaluate the effectiveness of a precision blended antibiotic treatment and prophylaxis nomogram for appendectomy in preparation for future large-scale dissemination by surgical quality collaboratives.
急性阑尾炎是世界上最常见的腹部外科急症,一生的风险为8.6% 男性为6.9%,女性为6.9%。在美国,急性阑尾炎影响28万人,并导致1 每年住院天数为100万天。阑尾切除术后手术部位感染的发生率 不复杂、未穿孔的阑尾炎仍然高得令人无法接受。最近的一篇综述报告了盆腔脓肿 阑尾切除术后发生率为9.4%。腹膜微生物污染的风险最高的是 当阑尾被横切时。无论手术方法如何,保留的阑尾残端总是 将阑尾粘膜和腔细菌暴露在通常无菌的腹膜腔内。因此,至关重要的是 最佳的抗生素组织暴露发生在手术风险窗口期间。 急性阑尾炎的抗生素干预是复杂的。治疗性抗生素是从经验上开始的 急诊科,通常在阑尾切除前几个小时(通常需要等待4-18个小时)。因此,在 手术时,船上已经有治疗性抗生素,预防性抗生素的作用尚不清楚。 到目前为止,关于治疗性和预防性抗生素的混合使用还没有达成共识。 手术,在许多情况下,不进行预防,因为治疗性抗生素已经 已经被注射了。不幸的是,在这些情况下,抗生素组织水平可能低于最低限度 阑尾横切时的抑制浓度,因其半衰期较短且缺乏协议 与手术切开相关的给药时机。因此,附录,一个已知的微生物群库, 在阑尾切除过程中,结肠的管腔向腹膜开放,以保证一定水平的组织和 手术过程中腹膜微生物污染,增加SSI和脓肿形成的风险。A更多 急性阑尾炎患者个体化给药方法可降低SSI风险 不必要的抗生素使用,减少过量使用的风险,并遏制抗生素耐药性的发展。 我们假设,基于手术时间的个性化抗生素剂量可以 优化手术部位的组织抗生素暴露,避免使用不必要的抗生素(选择性 抗生素抗药性压力),并降低毒性。因此,我们的具体目标是1)描述 手术患者血浆、组织和手术部位组织中治疗性抗生素浓度的研究 2)设计治疗用β-内酰胺类抗生素的精确剂量图。 影响患者抗菌药物敏感性分布的定量组织PK-PD建模和模拟 人口统计和形态类型,以及在阑尾切除术中达到最佳组织暴露的时间;以及 3)试行和评估精确混合抗生素治疗和预防的有效性 用于阑尾切除术,为未来大规模传播做准备,由手术质量协作组进行。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Manjunath P Pai其他文献

Manjunath P Pai的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Manjunath P Pai', 18)}}的其他基金

Precision coordination of therapeutic and prophylactic antibiotics to reduce infection, toxicity, and emergence of resistance following acute abdominal surgery
精确协调治疗性和预防性抗生素,以减少急腹手术后的感染、毒性和耐药性的出现
  • 批准号:
    10670080
  • 财政年份:
    2021
  • 资助金额:
    $ 46.62万
  • 项目类别:
Precision coordination of therapeutic and prophylactic antibiotics to reduce infection, toxicity, and emergence of resistance following acute abdominal surgery
精确协调治疗性和预防性抗生素,以减少急腹手术后的感染、毒性和耐药性的出现
  • 批准号:
    10296732
  • 财政年份:
    2021
  • 资助金额:
    $ 46.62万
  • 项目类别:

相似国自然基金

Rh-N4位点催化醇类氧化反应的微观机制与构效关系研究
  • 批准号:
    22302208
  • 批准年份:
    2023
  • 资助金额:
    30.00 万元
  • 项目类别:
    青年科学基金项目
跨文化团队中团队协调机制和团队效能的研究:文化智力的视角
  • 批准号:
    71072055
  • 批准年份:
    2010
  • 资助金额:
    28.0 万元
  • 项目类别:
    面上项目
"锁住"的金属中心手性-手性笼络合物的动态CD光谱研究与应用开发
  • 批准号:
    20973136
  • 批准年份:
    2009
  • 资助金额:
    34.0 万元
  • 项目类别:
    面上项目
资金约束供应链中金融和运营集成决策研究
  • 批准号:
    70872012
  • 批准年份:
    2008
  • 资助金额:
    22.0 万元
  • 项目类别:
    面上项目
钌苯络合物的配位立体化学及其氢转移催化性能研究
  • 批准号:
    20773098
  • 批准年份:
    2007
  • 资助金额:
    28.0 万元
  • 项目类别:
    面上项目

相似海外基金

DNA repair pathway coordination during damage processing
损伤处理过程中 DNA 修复途径的协调
  • 批准号:
    10748479
  • 财政年份:
    2024
  • 资助金额:
    $ 46.62万
  • 项目类别:
Tumor-Targeted Multimodality Nanoscale Coordination Polymers for Chemo-Immunotherapy of Metastatic Colorectal Cancer
用于转移性结直肠癌化疗免疫治疗的肿瘤靶向多模态纳米配位聚合物
  • 批准号:
    10639649
  • 财政年份:
    2023
  • 资助金额:
    $ 46.62万
  • 项目类别:
Seizure, cognitive change and dementia: Understanding the use and safety of anti-seizure medications
癫痫、认知改变和痴呆:了解抗癫痫药物的使用和安全性
  • 批准号:
    10740534
  • 财政年份:
    2023
  • 资助金额:
    $ 46.62万
  • 项目类别:
SUPPORT SERVICES FOR HIV AIDS CLINICAL TRIAL NETWORKS
HIV 艾滋病临床试验网络的支持服务
  • 批准号:
    10872942
  • 财政年份:
    2023
  • 资助金额:
    $ 46.62万
  • 项目类别:
Coordination of DNA Metabolism by Replication Protein A
复制蛋白 A 协调 DNA 代谢
  • 批准号:
    10623523
  • 财政年份:
    2023
  • 资助金额:
    $ 46.62万
  • 项目类别:
The role of Cannabinoid Receptor 2 in cerebrovascular protection following traumatic brain injury
大麻素受体2在脑外伤后脑血管保护中的作用
  • 批准号:
    10607700
  • 财政年份:
    2023
  • 资助金额:
    $ 46.62万
  • 项目类别:
TUBERCULOSIS PREVENTION IN CHILDREN TWO TO LESS THAN 13 YEARS OF AGE WITH AND WITHOUT HIV
感染和未感染 HIV 的 2 岁至 13 岁以下儿童的结核病预防
  • 批准号:
    10872953
  • 财政年份:
    2023
  • 资助金额:
    $ 46.62万
  • 项目类别:
Mechanism of epidermal coordination during development and regeneration in zebrafish
斑马鱼发育和再生过程中表皮协调机制
  • 批准号:
    10643060
  • 财政年份:
    2023
  • 资助金额:
    $ 46.62万
  • 项目类别:
Identifying Factors to Improve Dental and Mental Health Care among People with HIV
确定改善艾滋病毒感染者牙科和心理保健的因素
  • 批准号:
    10906440
  • 财政年份:
    2023
  • 资助金额:
    $ 46.62万
  • 项目类别:
Collaborative Care Model for Perinatal Depression Support Services -- Population-Level Equity-Centered Systems Change (COMPASS-PLUS): A Hybrid Type 2 Cluster Randomized Trial
围产期抑郁症支持服务协作护理模式——以人口水平公平为中心的系统变革 (COMPASS-PLUS):混合 2 型集群随机试验
  • 批准号:
    10835287
  • 财政年份:
    2023
  • 资助金额:
    $ 46.62万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了